Showing 3361-3370 of 5773 results for "".
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-Based Point-of-Care (T-POC) Quantitative Testing Platformhttps://modernod.com/news/versea-ophthalmics-commences-phase-1-launch-of-novel-tear-based-point-of-care-t-poc-quantitative-testing-platform/2481745/Verséa Ophthalmics announced the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management o
- RestoringVision Appoints of Three Directors to its Leadership Teamhttps://modernod.com/news/restoringvision-appoints-of-three-directors-to-its-leadership-team/2481739/Nonprofit RestoringVision announced the appointment of three directors to its leadership team to strengthen its impact in solving the global vision crisis. This follows a year of growth, in which RestoringVision expanded its reach by 48 percent in 2022. In 2023, the organization aims to reac
- BVI Expands IOL Capacity with New Facility in Belgiumhttps://modernod.com/news/bvi-expands-iol-capacity-with-new-facility-in-belgium/2481738/BVI has announced the opening of a new facility in Liège, Belgium that increases the company's IOL business capacity. BVI says the facility will unlock new growth opportunities while reinforcing the company’s environmental, social, and governance (ESG) leaders
- Genentech Presents Post-Hoc Clinical and Real-World Data for Vabysmo at ASRShttps://modernod.com/news/genentech-presents-post-hoc-clinical-and-real-world-data-for-vabysmo-at-asrs/2481737/Genentech announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists (ASRS) annual meeting, which will be held from July 28-August 1 in Seattle. The data advance the clinical and real-world evidence supporting t
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th
- Harrow Acquires Santen’s Branded Ophthalmic Portfoliohttps://modernod.com/news/harrow-acquires-santens-branded-ophthalmic-portfolio/2481735/Harrow announced it is acquiring certain US and Canadian commercial rights to several branded ophthalmic products from Santen. According to an 8-K filing with the SEC, Harrow will make a one-time upfront payment of $8 million, with future near- and medium-term milestone
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- ChromaDex: Nicotinamide Riboside (NR) May be a Potential Therapeutic Strategy for Glaucoma Patientshttps://modernod.com/news/chromadex-nicotinamide-rrboside-nr-may-be-a-potential-therapeutic-strategy-for-glaucoma-patients/2481733/ChromaDex announced promising findings from two independent clinical study abstracts originally presented in April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigativ
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti